Valeant Model Not Sustainable, Allergan Says
This article was originally published in The Pink Sheet Daily
Allergan officially rejects Valeant’s buyout offer and lays out its case for staying independent on May 12. The Botox-maker looked to bolster shareholder confidence by increasing its guidance and sharing its business plan for the future.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.